Xbrane Biopharma: FDA Resubmission in 2022

Research Note

2022-07-04

14:16

Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.

FE

Filip Einarsson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.